The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.

Autor:	Díaz-Beyá M; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.; Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Brunet S; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain., Nomdedéu J; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain., Cordeiro A; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain., Tormo M; Hematology Department, Hospital Clínico, Valencia, Spain., Escoda L; Hematology Department, Hospital Joan XXIII, Tarragona, Spain., Ribera JM; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Hematology Department, Institut Català d'Oncologia (ICO)-Hospital Germans Trias i Pujol, Badalona, Spain., Arnan M; ICO, Hematology Department, Hospital Duran i Reynals, l'Hospitalet de Llobregat, Barcelona, Spain., Heras I; Hematology Department, Hospital Morales Meseguer, Murcia, Spain., Gallardo D; Hematology Department, ICO Josep Trueta, Girona, Spain., Bargay J; Hematology Department, Hospital de Son Llàtzer, Palma de Mallorca Hematology, Palma de Mallorca, Spain., Queipo de Llano MP; Hematology Department, Hospital Virgen de la Victoria, Malaga, Spain., Salamero O; Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain., Martí JM; Hematology Department, Hospital Mutua de Terrassa, Barcelona, Spain., Sampol A; Hematology Department, Hospital de Son Llàtzer, Palma of Mallorca, Spain., Pedro C; Hematology Department, Hospital de Mar, Barcelona, Spain., Hoyos M; Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain., Pratcorona M; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.; Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Castellano JJ; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain., Nomdedeu M; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.; Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Risueño RM; Josep Carreras Leukaemia Research Institute, Barcelona, Spain., Sierra J; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; Hematology Department and Biological Hematology Laboratory, Hospital de Sant Pau, Barcelona, IIB-Sant Pau Research Institute, Universitat Autonoma of Barcelona, Barcelona, Spain., Monzó M; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain., Navarro A; Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, Barcelona, Spain., Esteve J; Hematology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain.; Josep Carreras Leukaemia Research Institute, Barcelona, Spain.; University of Barcelona, Barcelona, Spain.
Jazyk:	angličtina
Zdroj:	Blood cancer journal [Blood Cancer J] 2015 Oct 02; Vol. 5, pp. e352. Date of Electronic Publication: 2015 Oct 02.
DOI:	10.1038/bcj.2015.76
Abstrakt:	Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P=0.0025), shorter leukemia-free survival (P=0.026) and higher cumulative incidence of relapse (P=0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P=0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu